Neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease are on the rise throughout the world as the population ages. These diseases represent a major threat to human health and have diverse effects, with some causing memory/cognitive impairments and others hindering patients’ ability to speak, breathe and/or move. Current treatments and medications are inadequate for treating these disorders and new, effective therapies are sorely needed.
Digital devices are helping researchers forge new paths to better understand and treat neurological disorders. Join this webinar to learn about the types of digital devices that are currently available as well as the key clinical insights that can be gained from their use.
Referencing a few examples of current studies underway, the speakers will share best practices for deploying digital devices into clinical trials of neurological disorders and the insights that continuous collection of physiological data enables. Finally, the speakers will discuss the current status of biomarkers in neurodegenerative disease research and the implications of digital biomarker data in clinical endpoints.
Ray Dorsey, MD, David M. Levy Professor of Neurology and Director of the Center for Health + Technology, University of Rochester
Dr. Ray Dorsey and his colleagues seek to enable anyone anywhere to receive care, participate in research and benefit from therapeutic advances. They have written Ending Parkinson’s Disease, a book that provides a prescription for ending this debilitating condition. Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. His research has been published in leading medical, neurology and economic journals and has been featured on National Public Radio, in the New York Times and in the Wall Street Journal. In 2015, the White House recognized him as a “Champion for Change” for Parkinson’s disease.Message Presenter
Mark Matson, MBA, Vice President, Sales and Licensing, MC10 Inc.
Mark Matson is a research professional with 25 years in drug development with long stints at Pfizer, MannKind Corp and IQVIA. Over his career, Matson has been involved in all aspects of drug development, including clinical and non-clinical development, portfolio and program management, formulation development, finance, licensing and sales. Matson holds an Honors Degree in Molecular and Cellular Biology from the University of Connecticut, an MBA from Rensselaer Polytechnic Institute and numerous graduate certificates from Harvard Business School.Message Presenter
Glen Frick, MD, PhD, FAAP, Senior Medical Director, Neuroscience, Ophthalmology & Women’s Health, Covance
Glen Frick is a Fellowship-Trained Pharmacologist and Board-Certified Pediatrician with nearly 20 years of extensive Phase I-IV clinical trial experience. Frick has held key leadership roles within the pharmaceutical industry, including GlaxoSmithKline, Wyeth/Pfizer, Shire and Endo. He has conducted clinical and translational medicine studies in Neurodegeneration, Respiratory, Inflammation, Psychiatry, Pain and Dermatology. Frick completed an MD/PhD program at SUNY-Downstate Medical Center, obtaining his PhD in Developmental Neural & Behavioral Science. He served as VP of Clinical Development & Operations at Endo Pharmaceuticals and was Chief Medical Officer at Clene Nanomedicine, a start-up biotech in Salt Lake City, Utah prior to joining Covance in the Neurology Group.Message Presenter
Who Should Attend?
Chief Development Officers, Chief Medical Officers and VPs/Directors/Managers of:
- Biomarker Development
- Clinical Affairs
- Clinical Operations
- Medical Affairs
- Project Management
- Regulatory Affairs
What You Will Learn
Join this webinar to learn about:
- An overview of current devices supporting monitoring and treatment of neurodegenerative disorders
- Newly available digital devices
- Clinical insights gleaned from digital device data
- Insights into regulatory authority acceptance of digital biomarker data
- Examples of digital biomarkers data usage and implications in clinical endpoints
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.